

Antonio D'alessio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6780928/publications.pdf>

Version: 2024-02-01

27
papers

1,112
citations

1039406

9
h-index

610482

24
g-index

28
all docs

28
docs citations

28
times ranked

971
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456. | 13.7 | 649 |
| 2 | Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012. | 3.6 | 114 |
| 3 | T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 397-409. | 1.8 | 59 |
| 4 | ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100347. | 2.6 | 57 |
| 5 | The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186. | 1.7 | 44 |
| 6 | Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152. | 1.3 | 42 |
| 7 | Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 253-264. | 1.5 | 20 |
| 8 | PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 887-897. | 1.8 | 17 |
| 9 | The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. <i>Current Opinion in Oncology</i> , 2021, 33, 386-394. | 1.1 | 13 |
| 10 | Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374. | | 13 |
| 11 | Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901. | 1.9 | 11 |
| 12 | New Frontiers in the Medical Therapy of Hepatocellular Carcinoma. <i>Chemotherapy</i> , 2022, 67, 164-172. | 0.8 | 10 |
| 13 | The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 177-191. | 1.8 | 9 |
| 14 | Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 927-939. | 1.1 | 9 |
| 15 | Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 401-413. | 1.9 | 9 |
| 16 | Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 681-691. | 1.9 | 7 |
| 17 | Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. <i>Drugs and Aging</i> , 2021, 38, 579-591. | 1.3 | 5 |
| 18 | Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 5665. | 1.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Treating patients with advanced hepatocellular carcinoma and impaired liver function: Broadening the reach of anti-cancer therapy. <i>Liver Cancer International</i> , 2021, 2, 31-32. | 0.2 | 4 |
| 20 | COVID-19 and liver cancer clinical trials: Not everything is lost. <i>Liver International</i> , 2020, 40, 1541-1544. | 1.9 | 3 |
| 21 | Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 204. | 1.1 | 3 |
| 22 | The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 425-435. | 1.9 | 3 |
| 23 | A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16195-e16195. | 0.8 | 3 |
| 24 | Back to the basics: How the preclinical rationale shapes the immunotherapy landscape for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 5-6. | 0.2 | 1 |
| 25 | Current options and future directions of systemic therapy for advanced biliary tract cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021, 2, . | 0.5 | 1 |
| 26 | Tumour burden score and immune-related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. <i>Liver Cancer International</i> , 0, , . | 0.2 | 0 |
| 27 | Reply. <i>Hepatology</i> , 2022, 76, E82-E83. | 3.6 | 0 |